Osteoporosis drug ban looms in Europe

The osteoporosis drug strontium ranelate looks set to be suspended in Europe due to cardiovascular safety concerns.

After an in-depth review, a European Medicines Agency sub-committee has concluded the drug's risk–benefit profile is "no longer favourable" and that it should not be used to treat osteoporosis.

The recommendation will now go to another EMA committee, which is expected to issue a final opinion between 20-23 January.

Some 17,000 Australians currently receive strontium ranelate (Protos) for the treatment of severe osteoporosis, according to manufacturer